Nasal Spray News and Research

RSS

Treating the cerebrospinal fluid to protect the brain from chemotherapy's toxic effects

Up to three quarters of patients receiving cancer chemotherapy suffer from "chemo brain" -; a long-term side effect that makes it harder to remember things, maintain attention, and learn new information. When it strikes children, whose brains are still developing, their schoolwork and self-esteem may suffer.

13 Sep 2022

Public health agencies adapt covid lessons to curb overdoses, STDs, and gun violence

Shannan Piccolo walked into a hotel with a tote bag full of Narcan and a speech about how easy it is to use the medicine that can reverse opioid overdoses.

17 Aug 2022

Novel peptide helps prevent seizures, protects neurons in research models of both Alzheimer's and epilepsy

A novel peptide augments the brain's natural mechanism to help prevent seizures and protect neurons in research models of both Alzheimer's and epilepsy, scientists report.

16 Aug 2022

Azelastine nasal spray could decrease SARS-CoV-2 load

A new study illustrated that early azelastine nasal spray therapy might lower the SARS-CoV-2 load among virus-infected patients.

11 Aug 2022

Music festivals embrace overdose reversal drugs, but fentanyl testing kits remain taboo

A 26-year-old was found dead at his campsite during the Bonnaroo Music and Arts Festival in 2019. The toxicology report linked his death to a grim trend that has only worsened since.

3 Aug 2022

Nasal spray highly effective against HIV and SARS-CoV-2 in animal models

The intranasal delivery of amph-protein vaccines is a potential approach to elicit a mucosal immune response against many infectious diseases.

26 Jul 2022

Researchers reveal the exceptional capacity of Omicron to evade the immune system

The current wave of COVID-19 highlights a particularly high risk of reinfection by the Omicron variant of SARS-CoV-2.

6 Jul 2022

Inhaled vaccines provide better protection and stronger immunity than nasal sprays, study confirms

McMaster University scientists who compared respiratory vaccine-delivery systems have confirmed that inhaled aerosol vaccines provide far better protection and stronger immunity than nasal sprays.

10 Jun 2022

Tiny shark-derived antibodies broadly neutralize most SARS-CoV-2 variants

Resarchers discuss the ability of shark-derived antibodies to protect against multiple variants of SARS-CoV-2.

23 May 2022

Study explores macromolecular viral entry inhibitors as broad-spectrum first-line antivirals with anti-SARS-CoV-2 activities

Researchers created polystyrene sulfonate with significantly different molar masses, constructed these polymers as an exterior around spherical gold nanoparticles of various sizes to improve multivalency effects, measured antiviral effects of the antivirals on numerous viruses in vitro, and investigated the method of interaction of the leads with SARS-CoV-2 and lentiviral particles.

13 May 2022

Marine bioactive compounds against SARS-CoV-2

A new review paper published in the journal Environmental Science and Pollution Research aimed to determine the possibilities of using biologically active compounds derived from various chemical classes of marine organisms against SARS-CoV-2 infection at various stages of the life cycle of the virus.

6 May 2022

Study shows polysaccharides of seaweed and abalone inhibit SARS-CoV-2 in vitro

A new study published in Marine Drugs evaluated the inhibitory effect of three polysaccharides, crude polysaccharide from Hizikia fusiforme (CPHF), crude polysaccharide from Sargassum horneri (CPSH), and crude polysaccharide from abalone viscera (CPAV) on the propagation of SARS-CoV-2 in vitro.

28 Apr 2022

New compound delivered in a nasal spray effectively treats delta variant infection in mice

Researchers have shown a new compound delivered in a nasal spray is highly effective in preventing and treating COVID-19 caused by the Delta variant in mice.

29 Mar 2022

Ethyl lauroyl arginine hydrochloride (ELAH) nasal spray as potent antiviral against SARS-CoV-2

Researchers evaluate the virucidal effects of ELAH against SARS-CoV-2 and human coronavirus-229E in a nasal spray formulation.

15 Mar 2022

Tannic acid plays a role in inhibiting three key molecular pathways involved in SARS-CoV-2 infection

Professor Charles Ramassamy and his postdoctoral researcher Mohamed Haddad at Institut national de la recherche scientifique, in collaboration with scientists from Université de Montréal, McGill University, and Université du Québec à Montréal, believe that tannic acid plays a role in inhibiting three important molecular pathways involved in the SARS-CoV-2 infection.

10 Mar 2022

Study assesses the effectiveness of e-cigarettes as a smoking cessation aid

Using e-cigarettes to stop smoking may result in fewer successful quit attempts than trying to quit using other smoking cessation aids, such as nicotine replacement therapy (NRT) or meds, suggests US research published online in the journal Tobacco Control.

8 Feb 2022

Novel approach to improve intranasal sprays used to treat respiratory viral infections

Researchers proposed a novel approach to improve intranasal sprays used to treat respiratory viral infections, including SARS-CoV-2 infections.

2 Feb 2022

Nano-bubbles containing ACE2 protein can block infection from broad strains of SARS-CoV-2

Scientists at Northwestern Medicine and The University of Texas MD Anderson Cancer Center have identified natural nano-bubbles containing the ACE2 protein (evACE2) in the blood of COVID-19 patients and discovered these nano-sized particles can block infection from broad strains of SARS-CoV-2 virus in preclinical studies.

21 Jan 2022

The tetrapeptide tuftsin effectively impairs the binding of SARS-CoV-2 S1 to ACE2

In their recent study posted to the preprint server bioRxiv*, the researchers from China have shown that tuftsin, a natural phagocytosis-stimulating peptide, can effectively impair the binding of SARS-CoV-2 spike S1 subunit to ACE2 receptor in a dose-dependent manner and therefore can be considered a potential drug against SARS-CoV-2 infection.

20 Jan 2022

Natural extracellular vesicles containing ACE2 protein could fight new SARS-CoV-2 variants

Scientists at The University of Texas MD Anderson Cancer Center and Northwestern Medicine have identified natural extracellular vesicles containing the ACE2 protein (evACE2) in the blood of COVID-19 patients that can block infection from broad strains of SARS-CoV-2 virus in preclinical studies. The study was published today in Nature Communications.